This article examines the impact of reduced kidney function on the safety and effectiveness of CAR T-cell therapy in lymphoma patients. The study found that CAR T-cell therapy can be effective in patients with reduced kidney function, although dose adjustments may be necessary. The study also found that patients with reduced kidney function had a longer stay in the intensive care unit, but there was no significant difference in severe side effects or overall survival compared to patients with normal kidney function. However, the study did find a higher non-relapse mortality rate in the reduced kidney function group, potentially due to longer ICU stays and higher grade immune effector cell-associated neurotoxicity syndrome. Further research is needed to explore the effects of dose reduction on outcomes in this population. [Extracted from the article]